US Pharma Deals Midyear Outlook 2026: Why Dealmakers Are Leaning Into Growth

Glenn Hunzinger, PwC's US Health Industries Leader, speaks with Dan Farrell, PwC's Health Services Deals Leader, about the forces shaping health services dealmaking in 2026. Despite ongoing reimbursement uncertainty, rising medical costs, and operational pressures, investors continue to deploy capital into assets with strong fundamentals and clear value creation opportunities. The conversation explores where capital is flowing, how AI is influencing investment decisions, and what dealmakers should prioritize in the second half of the year.
Discussion Highlights:
Resilient health services deal activity despite reimbursement uncertainty and rising medical costs
Investor focus on operational resilience, earnings durability, and clear value creation pathways
Continued momentum in physician medical groups and behavioral health organizations
AI's growing role in diligence, operational performance, and value creation strategies
Increased activity in portfolio optimization, carve-outs, and strategic capital allocation
Key priorities for dealmakers navigating growth and value creation in the second half of 2026

Speakers:
Glenn Hunzinger, US Health Industries Leader, PwC
Roel Van den Akker, US Pharma and Life Science Deals Leader, PwC
For additional insights on the pharmaceutical and life sciences deals landscape, check out our Pharmaceutical and Life Sciences: US Deals 2026 Midyear Outlook report, available now: https://www.pwc.com/us/en/industries/health-industries/library/pharma-life-sciences-deals-outlook.html

For more information, please visit us at: https://www.pwc.com/us/en/industries/health-industries/health-research-institute/next-in-health-podcast.html.